

STATE OF WEST VIRGINIA DEPARTMENT OF HUMAN SERVICES BUREAU FOR MEDICAL SERVICES

Alex J. Mayer Cabinet Secretary Cynthia Beane, MSW, LCSW Commissioner

West Virginia Medicaid Drug Utilization Review Board Minutes 05.21.2025

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair David Gloss, MD, Vice Chair Scott Brown, RPh Phillip Galapon, MD Lester Labus, MD Michael Lonsinger, PharmD Mary Nemeth-Pyles, MSN, RN, CS Kate Forman, PharmD C.K. Babcock, PharmD Michael Ballow, PharmD Chris Booth, PharmD

Members Absent:

Ernest Miller, DO

Department of Human Services (DoHS)/Bureau for Medical Services (BMS) Staff:

Vicki Cunningham, PharmD, Director of Pharmacy Gail Goodnight, PharmD Lori Moles, PharmD Doug Sorvig, Data Analyst Hyla Harvey, MD, WV Medicaid Medical Director William Hopkins, PharmD, Pharmacy Operations Manager

Other Contract/State Staff Present:

Priya Shah, PharmD, Drug Utilization Review Coordinator
Joe Bergondo, PharmD – Change Healthcare
Roberta Capp, MD – Optum Rx
Eric Sears, RPh -- Gainwell
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)
Cory Chambliss – Acentra Health
Scott Donald, PharmD – Acentra Health

1. **INTRODUCTIONS**

a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:00 PM (EST). The DUR Board and others introduced themselves.

2. APPROVAL OF MINUTES FROM FEBRUARY 26, 2025 DUR BOARD MEETING

a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion



3. OLD BUSINESS

a. None

4. **NEW BUSINESS**

- a. Speakers
 - i. None
- b. Updates from March 12, 2025 Pharmaceutical & Therapeutics (P&T) Committee Meeting
 - i. Dr. Joe Bergondo presented the PDL status updates from the March 12th, 2025 P&T meeting.
- c. Prior Authorization Criteria. Attachment A
 - i. **Zepbound**: approved with amendments
 - ii. Tryngolza: approved as presented
 - iii. Pyzchiva: approved as presented
 - iv. Alhemo: approved as presented
 - v. Nemluvio: approved as presented
 - vi. Xarelto 2.5mg: approved as presented

5. REPORTS—1ST QUARTER 2025

- a. Gainwell Technologies Quarterly Report: Mr. Eric Sears presented an overview of the 2025 First Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
- b. **Rational Drug Therapy Program:** Dr. Angela Wowczuk presented a summary of the prior authorization program for the First Quarter of 2025. Attachment C.
- c. **Acentra Health:** Dr. Scott Donald presented a summary of the RDUR interventions for the First Quarter of 2025. Attachment D.

6. OTHER BUSINESS

a. None

7. NEXT MEETING AND ADJOURNMENT

a. The meeting concluded at 5:00 PM (EST). The next meeting will be September 24, 2025

